Kinase inhibitor larotrectinib shows durable anti-tumor abilities in patients of all ages with 17 unique cancer diagnoses
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors with tropomyosin receptor kinase (TRK) fusions, gene mutations that switch on TRK genes, allowing cancer growth. The studies indicate larotrectinib as a potentially powerful new treatment approach for the approximately...
Obesity associated with longer survival for men with metastatic melanoma
Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal...
Smart bomb virus shows promise as brain tumor immunotherapy
A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma...
Findings suggests potential new area of focus for checkpoint blockade immunotherapy
Triple-negative breast cancer (TNBC), a highly aggressive, relapse-prone cancer that accounts for one-fourth of all breast cancers, could be the focus of a new area of study for immune checkpoint blockade therapy. A team of researchers at The University of Texas MD Anderson Cancer Center revealed that in TNBC a cell process called glycosylation is required for PD-L1/PD1 molecules to interact and identified exactly how and why glycosylation...
MD Anderson supports World Cancer Day through commitment to end cancer
The University of Texas MD Anderson Cancer Center and its 20,000 faculty and staff devoted exclusively to patient care, research, education...